ZEVRA THERAPEUTICS ($ZVRA) posted quarterly earnings results for Q4 2025 on Monday, March 9th. The company reported earnings of $1.16 per share, beating estimates of $0.05 by $1.11. The company also reported revenue of $34,130,000, beating estimates of $28,611,897 by $5,518,103.
Stock price change since market close: +21.71%
You can see Quiver Quantitative's $ZVRA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ZEVRA THERAPEUTICS Insider Trading Activity
ZEVRA THERAPEUTICS insiders have traded $ZVRA stock on the open market 11 times in the past 6 months. Of those trades, 2 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $ZVRA stock by insiders over the last 6 months:
- NEIL F. MCFARLANE (President and CEO) has made 0 purchases and 3 sales selling 125,125 shares for an estimated $1,189,519.
- ALVIN SHIH purchased 20,000 shares for an estimated $157,800
- JOSHUA SCHAFER (CCO) has made 0 purchases and 2 sales selling 13,875 shares for an estimated $126,300.
- TIMOTHY J. SANGIOVANNI (SVP, Finance & Corp Controller) has made 0 purchases and 2 sales selling 4,750 shares for an estimated $42,990.
- ADRIAN W QUARTEL (Chief Medical Officer) sold 4,533 shares for an estimated $40,035
- RAHSAAN THOMPSON (Chief Legal & Compliance) sold 4,080 shares for an estimated $36,009
- TAMARA A FAVORITO purchased 3,175 shares for an estimated $24,718
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ZEVRA THERAPEUTICS Hedge Fund Activity
We have seen 78 institutional investors add shares of ZEVRA THERAPEUTICS stock to their portfolio, and 92 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RUBRIC CAPITAL MANAGEMENT LP removed 1,958,318 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $18,623,604
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 1,943,000 shares (-46.6%) from their portfolio in Q3 2025, for an estimated $18,477,930
- ALTIUM CAPITAL MANAGEMENT LLC removed 1,287,333 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $12,242,536
- AIGH CAPITAL MANAGEMENT LLC removed 1,231,932 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $11,038,110
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 912,419 shares (-75.7%) from their portfolio in Q4 2025, for an estimated $8,175,274
- FMR LLC added 758,922 shares (+46.4%) to their portfolio in Q4 2025, for an estimated $6,799,941
- VELAN CAPITAL INVESTMENT MANAGEMENT LP removed 715,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $6,799,650
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ZEVRA THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $ZVRA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 11/06/2025
To track analyst ratings and price targets for ZEVRA THERAPEUTICS, check out Quiver Quantitative's $ZVRA forecast page.
ZEVRA THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $ZVRA recently. We have seen 2 analysts offer price targets for $ZVRA in the last 6 months, with a median target of $24.0.
Here are some recent targets:
- Kristen Kluska from Cantor Fitzgerald set a target price of $24.0 on 11/06/2025
- Sumant Kulkarni from Canaccord Genuity set a target price of $24.0 on 11/06/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
